All In Biotech

Drug Trial Radar · NCT05076019

Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement

Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 266 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

266

Planned (sponsor's estimate)

Start

Feb 1, 2022

Primary completion

Dec 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Odense Patient Data Explorative Network; GCP-unit at Odense University Hospital
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery. The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to examine the ability of a clinically durable Atorvastatin prophylactic regime to prevent the development of POAF and other postoperative complications in these patients. Patients will be randomized to Atorvastatin 80mg or placebo 7 to 14 days preoperative until 30 days postoperative - a total of 37 to 44 days of treatment. The medication will be double blinded. The randomized studie will address the following hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that 1\) 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80 mg daily reduces the incidence of POAF in statin-naïve patients.

Conditions

  • Postoperative Atrial Fibrillation

Interventions

  • Atorvastatin 80mgDrug

    Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

  • PlaceboDrug

    Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with POAF - In-hospitalTime frame: In-hospital up to 10 days
  2. Number of Participants with POAF - EarlyTime frame: Early (≤30 days) incidence of POAF
  3. Total duration of POAF - In-hospitalTime frame: In-hospital up to 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Odense University Hospital

    Odense, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.